# Vinorelbine (Oral) Plus Trastuzumab for 1st-line Treatment of HER2/Neu Overexpressing Breast Cancer

> **NCT00433095** · PHASE2 · COMPLETED · sponsor: **Ludwig-Maximilians - University of Munich**

## Conditions studied

- Carcinoma Breast Stage IV

## Interventions

- **DRUG:** Navelbine
- **DRUG:** Herceptin
- **DRUG:** Navelbine (oraly)

## Key facts

- **NCT ID:** NCT00433095
- **Lead sponsor:** Ludwig-Maximilians - University of Munich
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2011-03-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00433095

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00433095, "Vinorelbine (Oral) Plus Trastuzumab for 1st-line Treatment of HER2/Neu Overexpressing Breast Cancer". Retrieved via AI Analytics 2026-07-04 from https://api.ai-analytics.org/clinical/NCT00433095. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*